ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer
These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.

These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.
During HUAWEI CONNECT 2025, Leo Chen, Senior Vice President, President of Enterprise Sales, Huawei, emphasised the focus is on how to harness AI’s full potential.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?
Trump blames Covid-19 drugmakers for fuelling CDC turmoil
Oxford University and Ellison Institute link for AI vaccine research